产品名称	Ziltivekimab (anti-IL-6), IgG 受体和转运体的 Fc 片段抗体
别名	泽韦奇单抗 \| 齐尔替基单抗（抗 IL-6）
英文别名	Interleukin BSF 2 antibody \| B cell differentiation factor antibody \| B cell stimulatory factor 2 antibody \| B-cell stimulatory factor 2 antibody \| BSF 2 antibody \| BSF-2 antibody \| BSF2 antibody \| CDF antibody \| CTL differentiation factor antibody \| Cyto
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	IL6
种属反应性	人(Human)
偶联	Unconjugated
作用类型	结合剂
作用机制	IgG 受体和转运体的 Fc 片段抗体

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.4 kDa (Light Chain) & 49.7 kDa (Heavy Chain), under reducing conditions; 175.3 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0.
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	2226654-05-1
分子类型	抗体

图片

ELISA: Ziltivekimab (anti-IL-6) (Ab175709)

Ziltivekimab (anti-IL-6) (Ab175709) - ELISA
Immobilized hu-IL-6 at 2 μg/mL can bind Ziltivekimab (anti-IL-6) (Ab175709) with the EC₅₀ of 103.3 ng/mL.

SEC: Ziltivekimab (anti-IL-6) (Ab175709)

Ziltivekimab (anti-IL-6) (Ab175709) - SEC
The purity of Ziltivekimab (anti-IL-6) (Ab175709) is more than 95% verified by HPLC.

关联靶点（人）

FCGRT Tclin IgG 受体 FcRn 大亚基 p51(IgG receptor FcRn large subunit p51) (0 活性数据)

点击查看靶蛋白信息： FCGRT

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

IL6 Tclin 白细胞介素-6(Interleukin-6) (0 活性数据)

点击查看靶蛋白信息： IL6

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

FCGRT Tclin IgG receptor FcRn large subunit p51 (445 活性数据)

点击查看靶蛋白信息： FCGRT

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

技术规格说明书

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1114054	分析证书	24-11-20	Ab175709
ZJ24F1114053	分析证书	24-11-20	Ab175709
ZJ24F1114052	分析证书	24-11-20	Ab175709
ZJ24F0404190	分析证书	24-04-07	Ab175709
ZJ24F0404189	分析证书	24-04-07	Ab175709
ZJ24F0404188	分析证书	24-04-07	Ab175709

可替换产品

参考文献

1. Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S et al.. (2011) Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.. J Mol Biol, 411 (4): (791-807). [PMID:21723291] [10.1021/op500134e]
2. Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y et al.. (2016) A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.. Cancer Res, 76 (2): (480-90). [PMID:26744529] [10.1021/op500134e]
3. Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH. (2015) IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.. Arch Pharm Res, 38 (5): (575-84). [PMID:25648633] [10.1021/op500134e]
4. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] [10.1021/op500134e]
5. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014) Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.. MAbs, 6 (3): (774-82). [PMID:24670876] [10.1021/op500134e]
6. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] [10.1016/j.immuni.2019.03.026]
7. Q Y Chen. (1992-09-01) [Stable and efficient expression of human interleukin-6 cDNA in mammalian cells after gene transfer].. Zhonghua zhong liu za zhi [Chinese journal of oncology], 14 ((5)): (340-344). [PMID:1291290]
8. H C van Zaanen,R P Koopmans,L A Aarden,H J Rensink,J M Stouthard,S O Warnaar,H M Lokhorst,M H van Oers. (1996-09-15) Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.. The Journal of clinical investigation, 98 ((6)): (1441-1448). [PMID:8823310]
9. Kim D, Won HY, Hwang ES, Kim YK, Choo HP.. (2017) Synthesis of benzoxazole derivatives as interleukin-6 antagonists.. Bioorg Med Chem, 25 (12): (3127-3134). [PMID:28442260] [10.1016/j.bmc.2017.03.072]
10. May, L T LT, Shaw, J E JE, Khanna, A K AK, Zabriskie, J B JB and Sehgal, P B PB.. (1991) Marked cell-type-specific differences in glycosylation of human interleukin-6.. Cytokine, [PMID:1883960]
11. Lütticken, C C, Krüttgen, A A, Möller, C C, Heinrich, P C PC and Rose-John, S S.. (1991) Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6.. FEBS letters, (6): [PMID:2037043]
12. Clogston, C L CL, Boone, T C TC, Crandall, B C BC, Mendiaz, E A EA and Lu, H S HS.. (1989) Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor.. Archives of biochemistry and biophysics, [PMID:2472117]
13. Ming, J E JE, Cernetti, C C, Steinman, R M RM and Granelli-Piperno, A A.. (1989) Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium.. The Journal of molecular and cellular immunology : JMCI, [PMID:2610854]
14. Tonouchi, N N, Miwa, K K, Karasuyama, H H and Matsui, H H.. (1989) Deletion of 3' untranslated region of human BSF-2 mRNA causes stabilization of the mRNA and high-level expression in mouse NIH3T3 cells.. Biochemical and biophysical research communications, (15): [PMID:2789513]
15. Zilberstein, A A, Ruggieri, R R, Korn, J H JH and Revel, M M.. (1986) Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.. The EMBO journal, [PMID:3023045]
16. Wong, G G GG, Witek-Giannotti, J J, Hewick, R M RM, Clark, S C SC and Ogawa, M M.. (1988) Interleukin 6: identification as a hematopoietic colony-stimulating factor.. Behring Institute Mitteilungen, [PMID:3266463]
17. Van Damme, J J and 5 more authors.. (1988) Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:3279116]
18. Brakenhoff, J P JP, de Groot, E R ER, Evers, R F RF, Pannekoek, H H and Aarden, L A LA.. (1987) Molecular cloning and expression of hybridoma growth factor in Escherichia coli.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:3320204]
19. Yasukawa, K K and 6 more authors.. (1987) Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene.. The EMBO journal, [PMID:3500852]
20. May, L T LT, Helfgott, D C DC and Sehgal, P B PB.. (1986) Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3538015]
21. Haegeman, G G and 5 more authors.. (1986) Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts.. European journal of biochemistry, (15): [PMID:3758081]
22. Breton, J J and 8 more authors.. (1995) Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond.. European journal of biochemistry, (15): [PMID:7851440]
23. Nishimura, C C, Watanabe, A A, Gouda, H H, Shimada, I I and Arata, Y Y.. (1996) Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy.. Biochemistry, (9): [PMID:8555185]
24. Somers, W W, Stahl, M M and Seehra, J S JS.. (1997) 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling.. The EMBO journal, (3): [PMID:9118960]
25. Xu, G Y GY and 6 more authors.. (1997) Solution structure of recombinant human interleukin-6.. Journal of molecular biology, (2): [PMID:9159484]
26. Fishman, D D and 6 more authors.. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.. The Journal of clinical investigation, (1): [PMID:9769329]
27. Foster, C B CB and 11 more authors.. (2000) An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus.. Blood, (1): [PMID:11001912]
28. Ota, N N and 8 more authors.. (2001) A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density.. Journal of human genetics, [PMID:11355017]
29. Chung, Hye Won HW and 8 more authors.. (2003) Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women.. Journal of human genetics, [PMID:12768442]
30. Nemeth, Elizabeta E and 6 more authors.. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.. The Journal of clinical investigation, [PMID:15124018]
31. Wolsk, Emil E, Mygind, Helene H, Grøndahl, Thomas S TS, Pedersen, Bente K BK and van Hall, Gerrit G.. (2010) IL-6 selectively stimulates fat metabolism in human skeletal muscle.. American journal of physiology. Endocrinology and metabolism, [PMID:20823453]
32. Ellingsgaard, Helga H and 20 more authors.. (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.. Nature medicine, (30): [PMID:22037645]
33. Taniguchi, Koji K and 17 more authors.. (2015) A gp130-Src-YAP module links inflammation to epithelial regeneration.. Nature, (5): [PMID:25731159]
34. Tagliabracci, Vincent S VS and 14 more authors.. (2015) A Single Kinase Generates the Majority of the Secreted Phosphoproteome.. Cell, (18): [PMID:26091039]
35. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003]
36. Hirano, T T and 9 more authors.. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.. Nature, [PMID:3491322]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Ziltivekimab (anti-IL-6), IgG 受体和转运体的 Fc 片段抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器